EG-2201

Synthetic cannabinoid

EG-2201
[[File: Chemical structure of EG-2201 |frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	1445752-09-9
PubChem	11902500
DrugBank
ChemSpider	10021209
KEGG

EG-2201 is a synthetic cannabinoid that has been used as a designer drug. It is a potent agonist of the cannabinoid receptors, which are part of the endocannabinoid system in the human body. This compound is structurally related to other synthetic cannabinoids such as AM-2201 and JWH-018.

Chemical Structure and Properties

EG-2201 is chemically classified as an indole-based synthetic cannabinoid. Its IUPAC name is (1-(5-fluoropentyl)-1H-indol-3-yl)(4-ethylnaphthalen-1-yl)methanone. The compound features a fluoropentyl chain, which is a common modification in synthetic cannabinoids to enhance potency and receptor affinity.

The molecular formula of EG-2201 is C₂₅H₂₄FN₁O₁, and it has a molecular weight of approximately 373.47 g/mol. The presence of the fluorine atom in the pentyl chain is a notable feature that distinguishes it from other cannabinoids.

Pharmacology

EG-2201 acts as a full agonist at the CB₁ and CB₂ receptors, which are the primary targets of cannabinoids in the body. These receptors are part of the G protein-coupled receptor family and are involved in a variety of physiological processes, including pain sensation, mood regulation, and appetite control.

The activation of CB₁ receptors by EG-2201 can lead to psychoactive effects similar to those produced by tetrahydrocannabinol (THC), the active component of cannabis. However, synthetic cannabinoids like EG-2201 can be significantly more potent than THC, leading to increased risk of adverse effects.

Legal Status

Due to its potential for abuse and lack of medical use, EG-2201 has been classified as a controlled substance in many jurisdictions. It is often included in legislation targeting synthetic cannabinoids and other novel psychoactive substances.

Health Risks and Toxicity

The use of EG-2201 has been associated with a range of adverse health effects. These can include tachycardia, hypertension, nausea, vomiting, anxiety, and hallucinations. In severe cases, use of synthetic cannabinoids can lead to seizures, renal failure, and even death.

The variability in potency and the presence of unknown impurities in synthetic cannabinoid products further increase the risk of toxicity. Users may experience unpredictable effects, and there is a significant risk of overdose.

Synthesis and Detection

The synthesis of EG-2201 involves the reaction of 5-fluoropentylindole with 4-ethylnaphthoyl chloride. This process requires specialized knowledge in organic chemistry and access to controlled precursors.

Detection of EG-2201 in biological samples can be challenging due to its structural similarity to other synthetic cannabinoids. Advanced analytical techniques such as mass spectrometry and gas chromatography are typically employed for its identification.

Related Pages

• Synthetic cannabinoid
• Cannabinoid receptor
• Designer drug
• AM-2201
• JWH-018